Free Trial
→ The unusual signal flashing green again (From ProsperityPub) (Ad)

Celularity Q1 2024 Earnings Report

Celularity logo
$1.77 -0.11 (-5.69%)
As of 03/28/2025 03:59 PM Eastern
Earnings History

Celularity EPS Results

Actual EPS
-$1.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Celularity Revenue Results

Actual Revenue
$14.68 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Celularity Announcement Details

Quarter
Q1 2024
Date
10/16/2024
Time
N/A

Conference Call Resources

Remove Ads

Celularity Earnings Headlines

Celularity extiende vencimiento de deuda y emite acciones a inversionista
March 23, 2025 | es.investing.com
Celularity extends debt maturity, issues stock to investor
March 23, 2025 | uk.investing.com
30-year market phenomenon opens up overnight opportunity
Imagine this: When things worked out, you woke up, checked your account, and saw that you’ve made money overnight. Sounds like a dream, right? Well, what if that wasn’t a dream anymore? Earning while you sleep isn’t easy, and it definitely doesn’t happen overnight for most people.
March 29, 2025 | ProsperityPub (Ad)
Celularity receives FDA TRG recommendation letters for Natalin, Acelagraft
February 25, 2025 | msn.com
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
February 25, 2025 | markets.businessinsider.com
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
February 25, 2025 | globenewswire.com
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU), a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

View Celularity Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles